Augmedix, Inc. (AUGX)
- Previous Close
2.3300 - Open
2.3200 - Bid 2.3100 x 200
- Ask 2.3500 x 200
- Day's Range
2.3200 - 2.3250 - 52 Week Range
0.7300 - 6.2500 - Volume
2,184 - Avg. Volume
899,385 - Market Cap (intraday)
114.92M - Beta (5Y Monthly) -0.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4700 - Earnings Date Nov 4, 2024 - Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.52
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was formerly known as Malo Holdings Corporation and changed its name to Augmedix, Inc. in October 2020. The company was founded in 2013 and is headquartered in San Francisco, California.
www.augmedix.com1,430
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AUGX
View MorePerformance Overview: AUGX
Trailing total returns as of 9/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AUGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AUGX
View MoreValuation Measures
Market Cap
115.17M
Enterprise Value
112.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.27
Price/Book (mrq)
11.00
Enterprise Value/Revenue
2.18
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-46.23%
Return on Assets (ttm)
-30.61%
Return on Equity (ttm)
-329.78%
Revenue (ttm)
51.58M
Net Income Avi to Common (ttm)
-23.85M
Diluted EPS (ttm)
-0.4700
Balance Sheet and Cash Flow
Total Cash (mrq)
28.22M
Total Debt/Equity (mrq)
241.31%
Levered Free Cash Flow (ttm)
-11.66M